Tumor Necrosis Factor Delivery System Development

Tumor necrosis factor (TNF) is a protein molecule produced by immune cells that leads to inflammation and apoptosis, making TNF delivery crucial in the treatment of chronic inflammatory diseases. TNF has a short half-life in vivo and easy to adverse effects. So developing novel TNF delivery systems has promising applications. CD Formulation is an industry leader in the development of novel drug delivery systems, and we are committed to developing high-quality TNF delivery systems that provide researchers with effective and reliable cytokine therapy solutions.

Figure 1. A schematic diagram of the concept of "non-conjugated ligand-mediated RNA delivery" by TNF-α. (Zhao Y, et al. 2022)

Advantages for Developing Tumor Necrosis Factor Delivery System

TNF delivery system delivery system utilizes the unique physiological functions of cells to deliver drugs targeted to the lesion area, which is the most complex and intelligent drug delivery system at present. Compared with the traditional drug delivery system, TNF delivery system has unique advantages in long circulation in vivo, targeting, biocompatibility, breaking through physiological barriers, etc. TNF delivery system is the best carrier to realize multi-functional drug delivery.

Our Tumor Necrosis Factor Delivery System Development Process

Formulation Design

Our scientists analyze the physicochemical properties of TNF and systematically design optimal formulations. This includes selecting suitable carriers, such as liposomes, microspheres, or nanoparticles, to encapsulate TNF and protect it from degradation.

Optimizing Parameters

We validate various parameters to ensure that the drug delivery systems developed achieve optimal drug loading, encapsulation rate and release characteristics.

Encapsulation Technology

In order to protect TNF-delivered drugs from degradation, we select appropriate encapsulation technologies to achieve high encapsulation efficiency.

In Vivo Evaluation

Our TNF delivery systems are rigorously tested in vivo on suitable animal models to evaluate their pharmacokinetic characteristics, safety, and effectiveness. By doing this step, we can improve the delivery method and adjust the formulation parameters depending on biological reaction data.

Application of Tumor Necrosis Factor Delivery System Development

• Kill or inhibit tumor cells. TNF can kill certain tumor cells (cytolytic action) or inhibit proliferation (cytostatic action) both in vivo and in vitro. The sensitivity of cells to exogenous TNF can be changed by inducing or inhibiting the expression of endogenous TNF. Macrophage membrane-bound TNF may be involved in the killing of target cells.
• Promote cell proliferation and differentiation. TNF promotes the expression of NHC class I antigen in T cells, enhances the proliferation of IL-2-dependent thymocytes and T cells, promotes the production of lymphokines such as IL-2, CSF and IFN-γ, and enhances the proliferation of B cells stimulated by mitogens or foreign antigens. TNF-α has a growth factor-like effect on certain tumor cells and cooperates with the pro-proliferative effects of EGF, PDGF and insulin to promote the expression of EGF receptors.
• Improve the phagocytic capacity of neutrophils. Increases the production of superoxide anions and stimulates cell degranulation and secretes myeloperoxidase.
• Anti-infective. For example, it inhibits the growth of Plasmodium, inhibits virus replication, inhibits viral protein synthesis, virus particle production and infectivity, and can kill virus-infected cells.

Highlights of Our Tumor Necrosis Factor Delivery System Development Services

• Experienced. Our scientists have years of expertise in drug development and ensure quality drug development services to our clients.
• Customized solutions. We offer custom development of TNF delivery systems for specific therapeutic targets. We provide a consultative approach and work closely with our clients to best meet their project needs.
• High-quality. We always adhere to the highest quality standards and aim to develop reliable, robust TNF delivery systems for our customers.

CD Formulation is an industry leader in tumor necrosis factor delivery system development, providing accurate and efficient services in drug development studies. If you are interested in us, please feel free to contact us.

Reference

1. Zhao Y, et al. Tumor necrosis factor alpha delivers exogenous inflammation-related microRNAs to recipient cells with functional targeting capabilities. Mol Ther. 2022, 30(9):3052-3065.